Table 6.
Comparison of direct and indirect evidences of treatments for psoriasis.
| Study | PASI 75 |
PGA |
AAE |
Nasopharyngitis |
Headache |
URTI |
Withdrawal |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p value | OR | p value | OR | p value | OR | p value | OR | p value | OR | p value | OR | p value | OR | |
| AM vs. PBO | ||||||||||||||
| Direct | 2.50 (0.70, 9.80) | 3.70 (0.35, 36.0) | 1.10 (0.33, 4.00) | 1.20 (0.28, 5.90) | 1.20 (0.32, 5.00) | – | 4.30 (0.45200) | |||||||
| Indirect | 0.544 | 4.50 (1.20, 17.0) | 0.756 | 5.50 (1.00, 30.0) | 0.988 | 1.10 (0.48, 2.70) | 0.989 | 1.20 (0.27, 5.20) | 0.555 | 2.10 (0.72, 5.60) | – | – | 0.538 | 2.00 (0.73, 5.90) |
| Network | 3.10 (1.30, 7.40) | 4.40 (1.02, 17.0) | 1.30 (0.65, 2.60) | 1.20 (0.47, 3.20) | 1.60 (0.69, 3.30) | – | 2.30 (0.89, 5.90) | |||||||
| Anti-IL12/23 vs. PBO | ||||||||||||||
| Direct | 51.0 (30.0, 86.0) | – | 1.10 (0.76, 1.50) | 1.30 (0.82, 2.50) | 1.10 (0.69, 2.00) | 1.10 (0.81, 1.60) | 0.65 (0.40, 1.10) | |||||||
| Indirect | 0.146 | 16.0 (3.70, 71.0) | – | – | 0.403 | 1.60 (0.68, 3.80) | 0.604 | 1.40 (0.66, 5.20) | 0.246 | 2.10 (0.86, 5.10) | 0.433 | 1.60 (0.69, 4.00) | 0.642 | 0.89 (0.26, 2.90) |
| Network | 43.0 (27.0, 67.0) | – | 1.10 (0.87, 1.50) | 1.50 (1.00, 2.30) | 1.50 (0.99, 2.20) | 1.20 (0.89, 1.70) | 0.65 (0.42, 0.99) | |||||||
| Anti-IL17 vs. PBO | ||||||||||||||
| Direct | 50.0 (28.0, 86.0) | – | 1.60 (1.10, 2.50) | 1.60 (0.96, 2.50) | 2.00 (1.20, 3.50) | 1.70 (1.00, 3.00) | 0.83 (0.47, 1.50) | |||||||
| Indirect | 0.101 | 140 (42.0, 960) | – | – | 0.356 | 1.10 (0.55, 2.30) | 0.558 | 1.20 (0.49, 2.70) | 0.396 | 1.30 (0.52, 3.10) | 0.494 | 1.20 (0.54, 2.70) | 0.394 | 0.49 (0.17, 1.50) |
| Network | 62.0 (37.0, 130) | – | 1.50 (1.00, 2.10) | 1.40 (0.94, 2.20) | 1.80 (1.10, 2.80) | 1.50 (1.00, 2.50) | 0.73 (0.45, 1.20) | |||||||
| Anti-IL17 vs. Anti-IL12/23 | ||||||||||||||
| Direct | 2.30 (0.85, 6.50) | 2.10 (0.43, 11.0) | 1.10 (0.62, 1.80) | 0.82 (0.39, 1.80) | 0.96 (0.46, 2.00) | 1.00 (0.49, 2.30) | 0.82 (0.36, 1.90) | |||||||
| Indirect | 0.224 | 1.10 (0.51, 2.30) | 0.463 | 4.60 (1.20, 20.0) | 0.266 | 1.60 (0.94, 2.80) | 0.568 | 0.87 (0.54, 2.20) | 0.399 | 1.50 (0.72, 3.30) | 0.500 | 1.50 (0.80, 2.80) | 0.387 | 1.30 (0.65, 2.60) |
| Network | 1.40 (0.76, 2.60) | 3.30 (1.20, 9.10) | 1.30 (0.88, 1.90) | 0.93 (0.57, 1.60) | 1.20 (0.60, 1.50) | 1.30 (0.79, 2.10) | 1.10 (0.64, 2.00) | |||||||
| Anti-TNF-α vs. Anti-IL12/23 | ||||||||||||||
| Direct | 0.40 (0.21, 0.79) | 0.51 (0.22, 1.10) | 1.10 (0.69, 1.80) | 1.00 (0.47, 2.20) | – | 0.77 (0.45, 1.30) | 1.10 (0.50, 2.30) | |||||||
| Indirect | 0.588 | 0.53 (0.25, 1.10) | 0.511 | 0.73 (0.29, 1.80) | 0.840 | 1.00 (0.54, 1.90) | 0.916 | 1.00 (0.48, 2.10) | – | – | 0.470 | 1.00 (0.63, 1.60) | 0.871 | 1.00 (0.54, 2.10) |
| Network | 0.44 (0.27, 0.73) | 0.62 (0.31, 1.20) | 1.10 (0.77, 1.50) | 1.00 (0.62, 1.70) | – | 0.91 (0.62, 1.30) | 1.00 (0.63, 1.60) | |||||||
| Anti-TNF-α vs. Anti-IL17 | ||||||||||||||
| Direct | 0.19 (0.03, 1.00) | 0.19 (0.02, 1.60) | – | – | – | – | 0.51 (0.13, 1.90) | |||||||
| Indirect | 0.568 | 0.33 (0.18, 0.65) | 0.931 | 0.17 (0.05, 0.54) | – | – | – | – | – | – | – | – | 0.368 | 1.00 (0.56, 1.90) |
| Network | 0.30 (0.17, 0.55) | 0.18 (0.06, 0.54) | – | – | – | – | 0.89 (0.52, 1.60) | |||||||
URTI: upper respiratory tract infection; PASI 75: ≥75% reduction in psoriasis area and severity index; PGA: Physician’s Global Assessment – minimal or cleared; AAE: all adverse events; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.